Abstract Details

Title Pseudobulbar Affect in Parkinsonian Syndromes

Topic Movement Disorders

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 10-016

Objective To examine the prevalence of pseudobulbar affect (PBA) in our patients with Parkinson disease (PD), dementia with Lewy bodies (DLB) and other Parkinsonian disorders, and whether its presence correlates with cognitive impairment.

Background PBA is frequently embarrassing and can be disabling in social and occupational situations. The incidence of PBA in PD, DLB and other Parkinsonian disorders is not clearly established, and it is unclear whom should be screened.

Design/Methods We performed retrospective chart review of patients with PD, DLB and other atypical or unspecified Parkinsonism who were screened for PBA using the Center for Neurologic Study- Lability Scale (CNS-LS) between February and September 2018 and whether those who had been screened had cognitive assessments through either the mini mental status examination (MMSE) or Montreal cognitive assessment (MoCA).

Results A total of 159 with PD, DLB or other Parkinsonism were screened, and 17.6% (28/159) met the positive threshold. This included 106 with PD or suspected PD, of whom 15% (16/106) screened positive, 23 with DLB or suspected DLB of whom 21.7% (5/23) screened positive, and 30 with atypical or unspecified Parkinsonism of whom 23.33% (7/30) screened positive. We identified 71 with documented cognitive testing (56 negative and 15 positive for PBA). There was no statistically significant difference in average MMSE or MMSE equivalent score in the positive vs negative groups (23.2 vs 24.6, p=0.23).

Conclusions PBA is a relatively common yet underdiagnosed and undertreated condition, which may lead to significant loss in quality of life for patients if untreated. Our results indicated that PBA quite prevalent across the spectrum of Parkinsonian disorders, but was slightly more prevalent in those with DLB and atypical Parkinsonism than in idiopathic PD. Those screening positive for PBA had a slightly lower average cognitive score but the results were not statistically significant.

Authors/Disclosures
Mazen Elkurd, DO (Baylor Scott & White Health) PRESENTER	No disclosure on file
Cameron Mohammadi, MD (MedStar Georgetown University Hospital)	Dr. Mohammadi has nothing to disclose.
Yasar A. Torres-Yaghi, MD	Dr. Torres-Yaghi has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acorda. Dr. Torres-Yaghi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Torres-Yaghi has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amneal. Dr. Torres-Yaghi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbott. Dr. Torres-Yaghi has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Torres-Yaghi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Dr. Torres-Yaghi has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sunovion .
Laxman Bahroo, DO, FAAN (Medstar Georgetown University Hospital)	Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Bahroo has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Supernus. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ipsen. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amneal. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acadia. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Revance. Dr. Bahroo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. Dr. Bahroo has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Abbvie. Dr. Bahroo has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Acorda. Dr. Bahroo has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Amneal. Dr. Bahroo has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Supernus. Dr. Bahroo has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Neurocrine. Dr. Bahroo has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sunovion. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Bahroo has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Lundbeck. Dr. Bahroo has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Merz.
Elizabeth E. Mundel, MD (MedStar Georgetown University Hospital)	No disclosure on file
Nadia Yusuf, MD	No disclosure on file
Fernando L. Pagan, MD, FAAN (Georgetown University Hospital Dept of Neurology)	Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Adamas. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kyowa Kirin. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sunovion. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for US World Meds. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Supernus. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acorda. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Adamas. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amneal. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sunovion. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurocrine. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sunovion. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Supernus. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Clinical Parkinsonism and related Disorders. Dr. Pagan has stock in Keiferx. The institution of Dr. Pagan has received research support from US World Meds. The institution of Dr. Pagan has received research support from Novartis.

��ɫ��

��ɫ��